Adverse Event Management and Patient Safety With Revumenib

Video content above is prompted by the following:

• What AEs are most commonly seen and how do you mitigate or manage these to optimize outcomes and maintain treatment continuity?
• Do these AEs align with what you’d expect when treating these patients?
• How do they compare across both approved and pipeline menin inhibitors?
• Differentiation syndrome, while manageable, is a critical safety concern,. hHow can clinicians best prepare to manage this?